Lipopolysaccharide (LPS) stimulates interleukin-1 (IL-1) and tumor necrosis factor a (TNFa) gene expression and synthesis in human peripheral blood mononuclear cells (PBMC). IL-1 can also induce PBMC to synthesize IL-I and TNFa In the present study, we used IL-1 receptor antagonist (IL-lra) to determine the relative contribution of an IL-I-positive feedback loop to the total amount of LPS-induced cytokine synthesis. Pretreatment of PBMC with human recombinant IL-lra reduced LPS-induced cytokine synthesis in a dosedependent manner (P < .001). Maximal inhibition was 33% for IL-la(P < .Ol), 43% for IL-lp (P = .001), and 20% for TNFa (P < .05). We consistently observed IL-lra suppression of LPS-induced cytokines in PBMC of 38 volunteers. However, this phenomenon was not specific for LPS; 1 pg/mL IL-lra IPOPOLYSACCHARIDE (LPS) is a cell wall compo-L nent of Gram-negative bacteria. When injected into humans, LPS causes fever' and hypotension.* The hemodynamic fluctuations are similar to those changes seen in septic shock; however, they are likely not due to the direct effects of LPS.3 These phenomena appear to be secondary to the induction of interleukin-1 (IL-1), tumor necrosis factor a (TNFa), and possibly other cytokines by LPS. This theory is supported by the presence of elevated serum levels of these cytokines during experimental endotoxemia4s5 and septic hock.^-^ Infusions of IL-1 or TNFa into humans can induce fever9 and hypotension.1°
L nent of Gram-negative bacteria. When injected into humans, LPS causes fever' and hypotension.* The hemodynamic fluctuations are similar to those changes seen in septic shock; however, they are likely not due to the direct effects of LPS.3 These phenomena appear to be secondary to the induction of interleukin-1 (IL-1), tumor necrosis factor a (TNFa), and possibly other cytokines by LPS. This theory is supported by the presence of elevated serum levels of these cytokines during experimental endotoxemia4s5 and septic hock.^-^ Infusions of IL-1 or TNFa into humans can induce fever9 and hypotension.1°
In addition to eliciting physiologic responses, IL-1 induces its own gene expression and synthesis'' and stimulates production of TNFa.12 TNFa also induces synthesis of IL-l.13 These positive feedback loops may contribute to the deterioration in patients with sepsis despite resolution of their bacteremia.
Based on these observations, the outcome of septic shock may be improved by inhibiting the actions of IL-1 or TNFa. Animal models of septic shock confirm that human recombinant IL-1 receptor antagonist (IL-lra), an 18-Kd polypeptide that blocks the binding of IL-1 to both IL-1 receptors (IL-lR)14-17 without exerting agonist a~tivity,'~J~ prevents Escherichia coli-induced shock20 and improves survival after lethal endotoxemia.21, 22 In baboons, antibodies to TNFa reduce mortality from a lethal infusion of live E coli.23 inhibited IL-1s synthesized in response to human recombinant IL-2 by 44% (P < .001), toxic shock syndrome toxin-1 by 26% (P < .05), and phorbol 12-myristate 13-acetate by 76% (P < .001). IL-lra added to PBMC 4 or 8 hours after stimulation with LPS still inhibited IL-1s synthesis by 44% (P c .001) or 25% (P = .Ol), respectively. The steady state messenger RNA levels of IL-1s were reduced in PBMC stimulated by LPS in the presence of IL-lra. In monocytes isolated by elutriation, IL-lra reduced LPS-induced IL-la by 16% (P c .001), IL-lp by 14% (P < .05), and TNFa by 24% (P = .01). We conclude that IL-1-induced IL-1 significantly contributes to LPS-induced cytokine synthesis.
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In the present study, we used a model of LPS-induced cytokine synthesis in human peripheral blood mononuclear cells (PBMC) to address two issues. First, we used IL-lra to determine the relative contribution of IL-1-induced cytokine synthesis to the total amount of LPS-induced cytokine production. Subsequently, we examined the capacity of IL-lra to block IL-1 after stimulation by LPS and the effect of IL-1 blockade on steady state IL-lp messenger RNA (mRNA) levels induced by LPS.
MATERIALS AND METHODS

IL-Ira and other reagents.
Human recombinant IL-lra was provided by Dr Robert C. Thompson (Synergen Inc, Boulder, CO). Human recombinant IL-2 was the gift of Cetus Corp (Emeryville, CA). Toxic shock syndrome toxin-1 (TSST-1) was kindly donated by Dr Takashi Ikejima (Tufts University School of Medicine, Boston, MA). LPS (from E coli 055:BS) and phorbol 12-myristate 13-acetate (PMA) were purchased from Sigma Chemical Co (St Louis, MO) and dissolved in RPMI 1640.
RPMI 1640 (Sigma) containing 10 mmol/L L-glutamine, 24 mmol/L NaHCO, (Mallinckrodt, Paris, KY), 10 mmol/L HEPES (Sigma), 100 U/mL penicillin, and 100 kg/mL streptomycin (Irvine Scientific, Santa Ana, CA), pH 7.4, was ultrafiltered using polysulfone hollow fiber filters (F40; Fresenius AG, Bad Homburg, Germany) to remove substances capable of inducing cytokine p r o d u c t i~n .~~ Human AB serum collected aseptically from one donor was heated for 45 minutes at 56°C. Indomethacin (Sigma) was dissolved in 95% ethanol at 10 mg/mL. PBMC were prepared from healthy human volunteers who had not used cyclooxygenase inhibitors during the previous 2 weeks.25 Blood was drawn into syringes containing heparin (20 UImL final concentration; LyphoMed Inc, Rosemont, IL). The PBMC fraction was isolated by centrifugation through Ficoll (Sigma) and Hypaque (90%; Winthrop Laboratories, New York, NY). Preparations of Ficoll-Hypaque used ultrafiltered water containing less than 100 pg/mL of endotoxin. PBMC were washed twice in sterile 0.9% sodium chloride (Abbott Laboratories, North Chicago, IL) before being resuspended at a concentration of 5 x lo6 cells/mL in RPMI. The cell suspension was supplemented with 2% vol/vol heat-inactivated AB serum and 1 kg/mL indomethacin. PBMC (500 kL) were then aliquoted into 5 mL polypropylene tubes that were placed in a 37°C water bath. Fifteen minutes later, 250 pL of either RPMI or IL-lra in RPMI was added. Cells were incubated an additional 30 minutes in the Human PBMC.
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37°C water bath. At that time, 250 pL of either RPMI or stimulus in RPMI was added. All cells were then incubated for 24 hours (unless stated otherwise) at 37°C in a humidified atmosphere containing 5% COa. After incubation, PBMC cultures were immediately frozen at -70°C.
PBMC cultures were subjected to three freeze-thaw cycles to yield maximal recovery of cell-associated cytokines." Samples were assayed in duplicate for I L -~C X ,~~ IL-lp,28 TNFcI,~~ or IL-lra30 by radioimmunoassay (RIA). Inhibition of IL-la binding in its RIA is unaffected by the presence of IL-lra; inhibition of IL-1p binding in its RIA is also unaffected by IL-lra. 31 The limit of detection for each RIA was 40 to 80 pg/mL IL-la, 80 to 160 pg/mL IL-lp, 80 to 160 pg/mL TNFa, and 80 to 160 pg/mL IL-lra.
PBMC (25 x lo6) were suspended in 5 mL RPMI with 2% AB serum and 1 pg/mL indomethacin. After 15 minutes in a 37°C water bath, 2.5 mL of either RPMI or IL-lra (4 pg/mL) was added. After another 30 minutes in the 37°C bath, 2.5 mL of either RPMI or LPS (40 ng/mL) was added. After 4,8,14, or 20 hours of incubation, PBMC were centrifuged at 200g for 5 minutes and then lysed in 4 mol/L guanidine isothi~cyanate.~~ Total RNA was obtained by centrifugation through 5.7 mol/L cesium chloride, 0.1 mol/L ethylenediaminetetraacetic acid for 18 hours at 100,OOOg at 17°C. Subsequently, RNA was precipitated overnight at -70°C by the addition of 0.1 vol 3 mol/L sodium acetate (pH 5.2) and 2.5 vol of cold ethanol. After centrifugation and lyophilization, RNA was resuspended in water and its concentration determined in a ultraviolet spectrophotometer. Using the methods of White and Ban~roft:~ serial dilutions of RNA were applied to wells of a multichamber manifold (SRC-76; Schleicher and Schuell, Keene, NH) onto a nylon membrane (Hybond-N; Amersham Corp, Arlington, IL) and fixed by short-wave ultraviolet radiation.
The IL-1p probe was a 1,075-bp fragment of the full-length complementary DNA for the human IL-1p precursor3 subcloned into pGEM2. The p-actin probe, a gift of Dr Brigitte Huber (Tufts University School of Medicine, Boston, MA) was the full length of chicken p-actin subcloned into pGEM3. DNA was labeled with 32P-dCTP by using a Random Primed DNA Labeling Kit (Boehringer Mannheim, Mannheim, Germany). Prehybridization, hybridization, washing, and autoradiography were performed using standard t e c h n i q~e s .~~ Monocytes were separated from total PBMC by countercurrent centrifugal elutriation (J-6B centrifuge, elutriation rotor, 20 mL elutriation chamber; Beckman Instruments Inc, Fullerton, CA) as described by Stevenson.36 PBMC were gently agitated to achieve a single cell suspension before being resuspended at a concentration of 1 x lo7 cells/mL in RPMI with 0.25% AB serum at 4°C. PBMC were then loaded at a flow rate of 5.25 mL/min into an elutriator maintained at 4°C and 56Og While flow rate was kept constant, centrifugation speed was decreased to 490g. Subsequently, flow rate was increased by 500 pL/min every 10 minutes. Cell fractions were collected in 50-mL aliquots and stored at 4°C until quantitation. As determined by staining with a-naphthylacetate esterase (Sigma) and Diff-Quik (Baxter Scientific Products, McGaw Park, IL), the populations designated 'monocytes' contained 93% to 97% monocytes. Viability of monocytes was greater than 99%, as determined by trypan blue exclusion and phagocytosis of latex beads. Those populations labeled 'lymphocytes' contained 87% to 97% lymphocytes, as determined by Diff-Quik staining. Viability of lymphocytes was greater than 99%, as determined by trypan blue exclusion. Monocytes and lymphocytes were washed twice before being resuspended in RPMI with 2% AB serum and 1 kg/mL indomethacin. Cells were stimulated as described for human PBMC.
Isolation of RNA.
Hybridization.
Elutriation.
Statistics. Statistical analysis was performed using the Student's t-test for paired samples and analysis of variance using Fischer's least significant difference. Data are expressed as mean f standard error of the mean (SEM).
RESULTS
Inhibition of LPS-induced IL-la, IL-l/3, and TNFa by IL-Ira is dose-dependent. PBMC from four donors were cultured in the presence of increasing concentrations of IL-lra for 30 minutes before stimulation with 10 ng/mL LPS. Inhibition of LPS-induced IL-la (Fig lA), IL-1p (Fig   lB) , and TNFa (Fig 1C) was dose-dependent (P < .001).
Inhibition required at least 500 ng/mL IL-lra. Maximal inhibition of LPS-induced cytokine synthesis occurred with 1 pg/mL IL-lra and was 33% for IL-la (P < .Ol), 43% for IL-lp (P = .001), 20% for TNFa (P < .05), and 25% for IL-6 (P = .05). The presence of indomethacin (1 pg/mL) did not modify the amount of inhibition by IL-lra (data not shown).
In the presence of LPS, stationary PBMC produce 16 ng/mL IL-lra and PBMC constantly rotated reportedly make 3 ng/mL IL-lra.30 In our experiment, stationary PBMC incubated with LPS produced 9.9 ? 1.2 ng/mL IL-lra. To assess the role of endogenous IL-lra, we concurrently performed the present experiment using constantly rotating PBMC. Rotating PBMC synthesized 1.2 ? 0.3 ng/mL IL-lra. However, the synthesis of IL-1 in LPS-stimulated PBMC was reduced to the same extent by IL-lra whether added to stationary or rotated cultures (data not shown).
IL-lra inhibits IL-I synthesis induced by other stimuli. The preceeding experiments suggested that IL-lra reduces LPS-induced cytokine synthesis by blocking an IL-1-positive feedback loop. If this was true, IL-lra should similarly inhibit other stimuli from inducing IL-1 p production. Therefore, PBMC from four new donors were incubated in the absence or presence of 1 p,g/mL IL-lra before stimulation with human recombinant IL-2 (1,000 U/mL), TSST-1 (100 ng/mL), or PMA (200 ng/mL). As shown in Fig 2A, IL-lra inhibited IL-1p synthesized in response to IL-2 by 44% (P < .OOl), TSST-1 by 26% (P < .05), and PMA by 76% (P < .001). Similar data were obtained for inhibition of IL-2-, TSST-1-, and PMA-induced IL-la synthesis (Fig 2B) .
Addition of IL-lra simultaneously or after stimulation with LPS reduces synthesis of IL-1. We reported that IL-lra added to PBMC 8 hours after stimulation with IL-lp inhibits IL-la, TNFa, and IL-6 synthesis.31 Therefore, we investigated whether IL-lra added concurrently with or subsequent to LPS could still inhibit LPS-induced IL-lp synthesis. PBMC from four donors were treated with IL-lra either 30 minutes before, at the same time, or at 4,8, or 24 hours after stimulation with LPS. Cells were incubated for 48 hours after the addition of LPS. As illustrated in Fig 3A, IL-lra added before or concurrent with LPS both resulted in 44% inhibition of LPS-induced IL-lP (P < .001). IL-lra added to PBMC 4 or 8 hours after LPS stimulation inhibited IL-1p synthesis by 44% (P < .001) or 25% (P = .Ol), respectively. Similar data were obtained for inhibition of LPS-induced IL-la by IL-lra (Fig 3B) . .I 
IL-Ira inhibits LPS-induced IL-lpgene expression.
Studies have shown that in THP-1 human monocytic leukemia cells37 and PBMC38 stimulated with LPS, IL-1p mRNA levels increase rapidly with a peak at 4 to 8 hours. In contrast, PBMC stimulated with IL-la show a more gradual increase in IL-1p mRNA levels with maximal levels occurring at 20 hours.38 Because IL-lra blocks the binding of IL-1 to the IL-1R on human monocytes,31 IL-lra might inhibit LPS-induced gene expression by preventing IL-1-induced IL-1 gene expression.
PBMC were preincubated in the absence or presence of IL-lra, stimulated with LPS, and then cultured for 4,8, 14, or 2o hours. Figure shows IL-lp mRNA increased rapidly with a peak at 4 to 8 hours.
IL-lra had no significant Time of IL-lra addition (hour) IL-Ira inhibits LPS-induced cytokine synthesis in monocytes. Monocytes and lymphocytes obtained by elutriation of PBMC from four donors were incubated in the absence or presence of IL-lra before stimulation with LPS. In monocytes, IL-lra reduced LPS-induced IL-la by 16% (P < .001), IL-1P by 14% (P < .05), TNFa by 24% (P = .Ol), and IL-6 by 8% (P = .01). Lymphocytes produced less than 200 pg/mL IL-la and IL-I@.
DISCUSSION
It is well established that LPS stimulates IL-1 and TNFa gene expression and synthesis. IL-1 also induces the synthesis of itself and TNFa. Using IL-lra, we showed that IL-1-induced IL-1 contributes significantly to the total amount of LPS-induced cytokine synthesis. IL-lra, at a concentration of 1 kg/mL, inhibited LPS-induced I L l a by 33%, IL-lp by 43%, and TNFa by 20%. This effect was dose-dependent; maximal inhibition of LPS-induced cytokine synthesis required 1 pg/mL IL-lra. Experiments with elutriated cells showed that lymphocytes are not required for IL-lra to exert its effect on monocytes.
LPS was not the only stimulus that induces IL-1 synthesis, nor was inhibition of stimulus-induced cytokine synthesis by IL-lra limited to LPS. IL-lra also reduced IL-1 synthesized in response to IL2, TSST-1, or PMA. An in vivo correlate of this phenomenon is the turpentineinduced sterile abscess. In this model, IL-lR blockade achieved by the daily injection of a murine anti-IL-1R monoclonal antibody (MoAb) prevented IL-1-mediated weight loss and plasma IL-6 in m i~e . 3~ IL-lra or a different MoAb directed against the IL-lR also blocked neutrophil accumulation in mice after intraperitoneal injection of proteose peptone. 40 The ability of IL-lra to inhibit cytokine synthesis induced by stimuli other than LPS does not support the argument that ILlra might block the binding of the LPS/LPS binding protein complex to monocytes.
Endogenous IL-lra synthesized in our PBMC cultures probably does not contribute to the inhibition of LPSinduced cytokine production. LPS-stimulated PBMC incubated in stationary tubes produced more IL-lra than PBMC incubated in constantly rotating tubes. Despite
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Addition of IL-lra before, at the same time, or 4 hours after LPS resulted in similar inhibition of LPS-induced IL-1 synthesis. IL-lra also reduced LPS-induced IL-1 even when IL-lra was added 8 hours after stimulation with LPS. This observation is consistent with our studies showing that IL-lra added up to 8 hours after stimulation with IL-1p inhibited IL-1-induced cytokine synthesis in PBMC. 31 Both findings imply that IL-lra could be efficacious even if administered after the onset of septic shock.
Previous studies have shown that LPS-induced IL-1p gene expression reaches peak levels at 4 to 8 hours before declining, whereas IL-la-induced IL-1 p gene expression increases gradually before maximal levels are observed at 20 hours.38 Dot-blot hybridization studies presented here show that IL-lra inhibited LPS-induced IL-1p gene expression. This effect was more pronounced at 20 hours rather than 8 hours after stimulation. The most likely explanation for this finding is that IL-lra is inhibiting LPS-induced IL-1 by interfering with an IL-1-positive feedback loop. By preventing IL-1 from binding to the IL-lR, IL-lra reduces transcription of the IL-1 gene. This hypothesis is supported by the work of Manson et a1,4l which showed inhibition of the production of IL-la, IL-lp, and TNFa in LPS-stimulated monocytes by using antisense phosphorothioate oligonucleotides complementary to the 5' untranslated and exon 6 regions of IL-1p mRNA. The phenomenon is more pronounced at 20 hours than at 8 hours because at 20 hours, IL-1 gene activation is less a consequence of the direct action of LPS but rather of the newly released IL-1.
On the basis of these findings, one would expect IL-lra to ameliorate diseases mediated via induction of IL-1 by LPS. Several models support this concept. Zucali et aI4* found that IL-1 induces granulocyte-macrophage colony-stimulating activity in fibroblasts. Subsequently, Henricson et a143 showed that administration of IL-lra to mice prevents LPS-induced colony-stimulating factor. In rats, Ulich et al" produced pneumonia by the intratracheal injection of IL-1 or LPS. Intratracheal coinjection of LPS and IL-lra resulted in less inflammation than injection of LPS alone. In animal models of endotoxemia, IL-lra has also been shown to prevent shock and improve surviva1. [20] [21] [22] It is unclear how much of the LPS-induced disease that is ameliorated by administration of IL-lra is due to reduced synthesis of IL-1 and TNFa. A TNFa-induced IL-1-positive feedback loop probably exists because anti-TNFa antibodies reduce circulating IL-1 and IL-6 levels in baboons infused with live E Therefore, reduction of circulating TNFa indirectly by IL-lra may contribute to a reduction in IL-1 levels.
